BusinessRitter Pharmaceuticals Announces 1-for-10 Reverse Stock SplitBy Nasdaq OMXMar 22, 2018, 3:35 PM UTC
BusinessRitter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 19, 2018, 10:35 AM UTC
BusinessChapman Global Medical Center Achieves National Accreditation and Recognition for Metabolic and Bariatric SurgeryBy Nasdaq OMXMar 8, 2018, 10:00 AM UTC
BusinessRitter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical TrialBy Nasdaq OMXJan 29, 2018, 2:01 PM UTC
BusinessMicroBiome Therapeutics Completes Series B Financing and Prepares to Launch First Microbiome Modulator ProductBy Nasdaq OMXNov 1, 2017, 11:00 AM UTC
BusinessRitter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXOct 31, 2017, 10:45 AM UTC
BusinessRitter Pharmaceuticals, Inc. Prices $23,000,000 Public OfferingBy Nasdaq OMXSep 29, 2017, 12:00 PM UTC
